GlassScriptPhysician profile
Cassidy Michaela Shive
NPI 1154068757
$8,026.04
in general payments reported to CMS, 2019-2025
22 companies · $19.09 in 2025
The $19.09 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $457 · 2023: $5,136 · 2024: $2,414 · 2025: $19.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,280 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,280.47 |
| Education | $288.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,734.81 | 2022-2025 | Austedo Xr, Austedo, Uzedy |
| Janssen Pharmaceuticals, INC | $930.39 | 2023-2024 | Invega Sustenna, Spravato, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $798.12 | 2023-2024 | Rexulti, Abilify Maintena, Nuedexta |
| Neurocrine Biosciences, INC. | $686.23 | 2022-2024 | Ingrezza |
| Abbvie INC. | $629.84 | 2022-2024 | |
| Supernus Pharmaceuticals, INC. | $571.76 | 2023-2024 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $467.70 | 2022-2024 | Caplyta |
| Alkermes, INC. | $397.98 | 2022-2024 | Aristada, Lybalvi |
| Uswm, LLC | $339.84 | 2022-2024 | Lucemyra, Zimhi |
| Axsome Therapeutics, INC. | $240.35 | 2022-2023 | Auvelity |
| Lundbeck LLC | $221.15 | 2022-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $183.05 | 2023 | Quviviq |
| Tris Pharma INC | $170.31 | 2023-2024 | Dyanavel Xr |
| Bausch Health US, LLC | $166.22 | 2022-2024 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $146.12 | 2022-2024 | Trintellix |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $92.57 | 2022-2023 | Belsomra |
| Noven Therapeutics, LLC | $78.81 | 2022-2024 | Xelstrym, Secuado |
| Vanda Pharmaceuticals INC. | $75.55 | 2023-2024 | Hetlioz, Fanapt |
| Corium, LLC | $27.45 | 2024 | Azstarys |
| Indivior INC. | $25.88 | 2023 | Sublocade |
| Sunovion Pharmaceuticals INC. | $22.62 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassidy Shive listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.